AR051844A1 - Uso de agonistas beta de estrogenos en desordenes o enfermedades cognitivas - Google Patents
Uso de agonistas beta de estrogenos en desordenes o enfermedades cognitivasInfo
- Publication number
- AR051844A1 AR051844A1 ARP050105297A ARP050105297A AR051844A1 AR 051844 A1 AR051844 A1 AR 051844A1 AR P050105297 A ARP050105297 A AR P050105297A AR P050105297 A ARP050105297 A AR P050105297A AR 051844 A1 AR051844 A1 AR 051844A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorders
- agonists
- strogen
- beta
- cognitive diseases
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 239000000556 agonist Substances 0.000 title 1
- 230000001149 cognitive effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 229940125388 beta agonist Drugs 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63714404P | 2004-12-17 | 2004-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051844A1 true AR051844A1 (es) | 2007-02-14 |
Family
ID=36143266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050105297A AR051844A1 (es) | 2004-12-17 | 2005-12-15 | Uso de agonistas beta de estrogenos en desordenes o enfermedades cognitivas |
Country Status (20)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1984028A2 (en) * | 2006-02-14 | 2008-10-29 | Wyeth a Corporation of the State of Delaware | Aqueous pharmaceutical formulations of er selective ligands |
| WO2010105035A2 (en) * | 2009-03-11 | 2010-09-16 | University Of South Florida | Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure |
| US10149982B2 (en) | 2009-03-11 | 2018-12-11 | University Of South Florida | Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment |
| US10758496B2 (en) * | 2014-09-02 | 2020-09-01 | The Regents Of The University Of California | Estrogen receptor ligand treatment for neurodegenerative diseases |
| WO2018183800A1 (en) * | 2017-03-30 | 2018-10-04 | Marquette University | Substituted (4'-hydroxyphenyl)cycloalkane and (4'-hydroxyphenyl)cycloalkene compounds and uses thereof as selective agonists of the estrogen receptor beta isoform for enhanced memory consolidation |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990078A (en) * | 1995-07-14 | 1999-11-23 | The Trustees Of Columbia University In The City Of New York | Means of increasing estrogen receptor levels in neural tissue |
| FR2739777B1 (fr) * | 1995-10-11 | 1997-11-14 | Cird Galderma | Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose |
| WO1998021946A1 (en) * | 1996-11-18 | 1998-05-28 | Internutria, Inc. | Composition and treatment for persistent reproductive transition symptoms |
| US20040092010A1 (en) * | 2002-04-15 | 2004-05-13 | Ariel Ruiz I Altaba | Method of proliferating and inducing brain stem cells to differentiate to neurons |
| TR200102992T2 (tr) * | 1999-04-16 | 2004-12-21 | Astrazeneca Ab | ß östrojen reseptörü ligandları. |
| JP2004515496A (ja) * | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | ベンズイミダゾール治療剤 |
| WO2002051821A1 (en) * | 2000-12-22 | 2002-07-04 | Astrazeneca Ab | Therapeutic compounds |
| US20030096264A1 (en) * | 2001-06-18 | 2003-05-22 | Psychiatric Genomics, Inc. | Multi-parameter high throughput screening assays (MPHTS) |
| DE60116109T2 (de) * | 2001-11-07 | 2006-09-07 | Schering Ag | In vitro Screening nach Liganden des Östrogenrezeptors |
| UA83620C2 (ru) * | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| TWI306450B (en) * | 2001-12-13 | 2009-02-21 | Wyeth Corp | Substituted phenyl naphthalenes as estrogenic agents |
| TW200301107A (en) * | 2001-12-13 | 2003-07-01 | Wyeth Corp | Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents |
| US6774248B2 (en) * | 2001-12-18 | 2004-08-10 | Wyeth | Substituted 2-phenyl benzofurans as estrogenic agents |
| WO2004026290A1 (en) * | 2002-09-19 | 2004-04-01 | Merck & Co., Inc. | Method for treating depression and/or anxiety |
| CL2004000985A1 (es) * | 2003-05-16 | 2005-01-14 | Wyeth Corp | Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc |
| US7157492B2 (en) * | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
| JP2008505095A (ja) * | 2004-07-01 | 2008-02-21 | ワイス | エストロゲンリガンドとしての四環式化合物 |
-
2005
- 2005-12-15 RU RU2007120254/14A patent/RU2007120254A/ru not_active Application Discontinuation
- 2005-12-15 EP EP05854149A patent/EP1824478A2/en not_active Withdrawn
- 2005-12-15 MX MX2007007347A patent/MX2007007347A/es unknown
- 2005-12-15 US US11/304,037 patent/US20060135574A1/en not_active Abandoned
- 2005-12-15 KR KR1020077013666A patent/KR20070086329A/ko not_active Withdrawn
- 2005-12-15 AR ARP050105297A patent/AR051844A1/es unknown
- 2005-12-15 TW TW094144391A patent/TW200637545A/zh unknown
- 2005-12-15 AU AU2005316561A patent/AU2005316561A1/en not_active Abandoned
- 2005-12-15 CN CNA2005800434508A patent/CN101321524A/zh active Pending
- 2005-12-15 BR BRPI0519111-4A patent/BRPI0519111A2/pt not_active IP Right Cessation
- 2005-12-15 PA PA20058656601A patent/PA8656601A1/es unknown
- 2005-12-15 CA CA002590258A patent/CA2590258A1/en not_active Abandoned
- 2005-12-15 JP JP2007546887A patent/JP2008524236A/ja active Pending
- 2005-12-15 GT GT200500370A patent/GT200500370A/es unknown
- 2005-12-15 WO PCT/US2005/045375 patent/WO2006065968A2/en not_active Ceased
-
2006
- 2006-01-03 PE PE2006000026A patent/PE20061113A1/es not_active Application Discontinuation
-
2007
- 2007-05-24 NO NO20072658A patent/NO20072658L/no not_active Application Discontinuation
- 2007-05-31 IL IL183604A patent/IL183604A0/en unknown
- 2007-06-14 NI NI200700152A patent/NI200700152A/es unknown
- 2007-06-15 ZA ZA200705103A patent/ZA200705103B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0519111A2 (pt) | 2008-12-23 |
| CN101321524A (zh) | 2008-12-10 |
| PA8656601A1 (es) | 2006-12-07 |
| WO2006065968A8 (en) | 2008-09-12 |
| IL183604A0 (en) | 2007-10-31 |
| AU2005316561A1 (en) | 2006-06-22 |
| MX2007007347A (es) | 2007-07-13 |
| RU2007120254A (ru) | 2009-01-27 |
| NO20072658L (no) | 2007-09-12 |
| WO2006065968A2 (en) | 2006-06-22 |
| PE20061113A1 (es) | 2006-11-06 |
| CA2590258A1 (en) | 2006-06-22 |
| WO2006065968A3 (en) | 2008-04-10 |
| TW200637545A (en) | 2006-11-01 |
| GT200500370A (es) | 2006-07-13 |
| NI200700152A (es) | 2008-06-17 |
| KR20070086329A (ko) | 2007-08-27 |
| JP2008524236A (ja) | 2008-07-10 |
| EP1824478A2 (en) | 2007-08-29 |
| ZA200705103B (en) | 2009-11-25 |
| US20060135574A1 (en) | 2006-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28933A1 (es) | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos | |
| HN2005029978A (es) | Formulaciones | |
| GT200600240A (es) | Anticuerpos monoclonales anti-trkb y usos de los mismos | |
| ECSP055818A (es) | Métodos y composiciones para inducir apoptosis en células de cáncer. | |
| AR061171A1 (es) | Proteinas de union al factor de crecimiento de hepatocitos (fch) | |
| CL2007001665A1 (es) | Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria. | |
| SV2010003559A (es) | Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos | |
| CR20110118A (es) | Tratamiento de enfermedades autoinmunes e inflamatorias | |
| CR7828A (es) | Oxialquilamidas de quinolina, isoquinolina y quinazolina y su uso como fungicidas | |
| AR063494A1 (es) | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 | |
| CL2011000301A1 (es) | Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer. | |
| UY34278A (es) | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades | |
| CR10900A (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso los mismos | |
| MX2009013332A (es) | Inhibidores de ire-1 alfa. | |
| SI1827441T1 (sl) | Kombinacije za zdravljenje bolezni, povezanih s celično proliferacijo | |
| EA200801551A1 (ru) | Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы | |
| AR066312A1 (es) | Uso de glucoproteinas de mucina en combinacion con agentes terapeuticos para tratar lesiones epiteliales y trastornos por deterioro de la funcion de la mucina | |
| UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
| CR7977A (es) | Anilidas de acido trifluorometil-tiofencarboxilico y su uso como fungicidas | |
| BRPI0519710A2 (pt) | aminoÁlcoois tricÍclicos, processo para sua preparaÇço e seu emprego como anti-inflamatàrio | |
| UY29777A1 (es) | Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión. | |
| BRPI0809970A2 (pt) | Antagonistas de cxcl 13 e seu uso para o tratamento de doenças inflamatórias | |
| NI200700152A (es) | Usos novedosos para agonistas de estrogeno beta | |
| UY29434A1 (es) | Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como inhibidores de la inflamacinn | |
| BRPI0506792A (pt) | derivados de furosemida como moduladores de hm74 e seu uso no tratamento de inflamação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |